

BIOLOGICS AND BIOSIMILARS & BIOPHARMA & BIOTHERAPEUTICS

October 24-25, 2018 | Boston, USA

Microfluidics: An advanced platform for pharmaceutical protein formulation

Sabiruddin Mirza

Harvard University, USA

One of the therapies which hold enormous potential for treating many terminal diseases includes protein-based therapies. Yet due to scarcity in development of universal technological approaches that develops protein formulations with targeted attributes blocks the clinical translation of these advanced therapies. The current study emphasized development of protein formulation with using droplet-based microfluidic technology which characterizes size, internal morphology, protein release profile and encapsulation efficiency.

Biography

Sabiruddin Mirza is currently a Senior Research Fellow at the School of Engineering and Applied Sciences at Harvard University, Cambridge, MA, USA and an Adjunct professor at the University of Helsinki, Helsinki, Finland. After several years in the full-time industry, he escaped to academia and earned his PhD degree in pharmaceutical technology from the University of Helsinki in 2007. His dissertation research has been awarded the 2008 American Association of Pharmaceutical Scientist's Outstanding Graduate Research Award in Pharmaceutical Technologies. His current research is focused on the engineering of advanced Nanosystems for drug delivery applications. In addition, his areas of expertise include pharmaceutical crystallization, cocrystallization and Nano crystallization, droplet based microfluidics and solid-state characterization, preformulation and formulation. Overall, his research has attracted around \$550 000 in sustained funding from the Academy of Finland, private foundations and industries. He is the author/coauthor of over 50 peer-reviewed articles and conference proceedings.

sabir@seas.harvard.edu

Notes: